GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » COGS-to-Revenue

Marksans Pharma (NSE:MARKSANS) COGS-to-Revenue : 0.47 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma COGS-to-Revenue?

Marksans Pharma's Cost of Goods Sold for the three months ended in Dec. 2023 was ₹2,728 Mil. Its Revenue for the three months ended in Dec. 2023 was ₹5,861 Mil.

Marksans Pharma's COGS to Revenue for the three months ended in Dec. 2023 was 0.47.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Marksans Pharma's Gross Margin % for the three months ended in Dec. 2023 was 53.45%.


Marksans Pharma COGS-to-Revenue Historical Data

The historical data trend for Marksans Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma COGS-to-Revenue Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.52 0.45 0.48 0.50

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.50 0.49 0.48 0.47

Marksans Pharma COGS-to-Revenue Calculation

Marksans Pharma's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=9213.58 / 18496.19
=0.50

Marksans Pharma's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2728.19 / 5861.27
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma  (NSE:MARKSANS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Marksans Pharma's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2728.19 / 5861.27
=53.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Marksans Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines